Efficacy of efavirenz in a mixed population of patients. Identification of drop-out causes;Valutazione dell'efficacia di efavirenz in una casistica mista. Rilievo delle cause di drop-out

Infezioni in Medicina

Volumn 10, Issue 3, 2002, Pages 163-168

  Sabbatani, Sergio ^a   Fulgaro, Ciro ^a   Rosticelli, Elena ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Drop out; Efavirenz

Indexed keywords

ANTIVIRUS AGENT; EFAVIRENZ; NELFINAVIR; NEVIRAPINE;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEPATITIS; ARTICLE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FISHER EXACT TEST; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPOTENCE; KRUSKAL WALLIS TEST; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PSYCHOSIS; RASH; SIDE EFFECT; STUDENT T TEST; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ERUPTIONS; DRUG EVALUATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; OXAZINES; PATIENT DROPOUTS; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0036396255     PISSN: 11249390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Staszewski S., Morales-Ramirez J., Tashima K.T., et al., for the Study 006 Team. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir and indinavir plus zidovudine and lamivudine in the treatment of HIV-infection in adults. N. Engl. J. Med. 341, 1865-1873, 1999.
2. Moyle G.J. Efavirenz: shifting the HAART paradigm in adult HIV-1 infection. Exp. Opin. Invest. Drugs 8, 473-486, 1999.
3. th Interscience Conference on Antiretroviral Agents and Chemotherapy, San Francisco, addendum. 1999. Abstract LB-22, p. 18.
4. Montaner J.S., Reiss P., Cooper D., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the Incas Trial. JAMA 279, 930-7, 1998.
5. th Conference on Retroviruses and Oppportunistic Infections, San Francisco, 2000, Abstract 510, p. 172.
6. Ruiz L., Negredo E., Domingo P., et al. Antiretroviral treatment simplification with nevirapine in PI-experienced patients with HIV-associated lipodystrophy: one-year prospective follow-up of a multicentre, randomised, controlled study: J. Acquir. Immune Defic. Syndr. 27, 229-236, 2001.
7. th Interscience Conference on Antiretroviral Agents and Chemotherapy, San Francisco, 1999, Abstract 2198, p. 535.
8. Martinez E., Conget I., Lozano I., et al. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13, 805-810, 1999.
9. th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000, Abstract 45, p. 83.
10. th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000, Abstract 48, p. 84.
11. th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000. Abstract 537, p. 176.
12. th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000. Abstract 49, p. 84.
13. Euroguidelines. European Guidelines for the Clincal Management and Treatment of HIV Infected Adults in Europe 2001. European AIDS Clinical Society (EACS).
14. Negredo E., Cruz L., Paredez R., et al. Virological, Immunological and Clinical Impact of Switching from Protease Inhibitors to Nevirapine or to Efvariren in Patients with Human Immunodeficiency Virus Infection and long-lasting viral suppression. Clin. Infect. Dis. 34, 504-510, 2002.
15. Sabbatani S., Cesari R. Cost Assessment of antiretroviral drugs used in the treatment of patients with HIV infection. Clin. Drug. Invest. 22, 253-262, 2002.
16. Banch J., Martinez E., Rousand A. et al. Preliminary Data of a prospective study on neuropsychatric side effects after initiation of efavirenz J. AIDS 27, 336-343, 2001.
17. Marzolini C., Telenti A., Decosted L.A. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients, AIDS 15, 71-75, 2001.
18. th International AIDS Conference, Durban, 2000. P. WePe B4238.
19. th International AIDS Conference, Durban, 2000. P. We Pe B4288.